Hyaluronic Acid Turbidimetric Assay Compared to Standard Method
|
By LabMedica International staff writers Posted on 13 Jan 2016 |
|
Image: The Hitachi 917 Automatic Disk-Chemistry Analyzer (Photo courtesy of Roche Diagnostics).
Circulating hyaluronic acid (HA) in human adults is primarily produced in the peripheral soft connective tissue and transported to the systemic circulation via lymph drainage and the majority of HA is removed from circulation by hepatic elimination.
HA is essentially non-immunogenic, which has excluded direct immunochemical methods of measurement. To accommodate this, several advanced methods of measurements have been used including enzymatic degradation; hyaluronic-binding protein (HABP) linked enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography.
Scientists at the Nordsjaellands Hospital, University of Copenhagen, (Denmark) and their colleagues measured HA concentrations in 39 samples of serum from 39 randomly selected intensive care unit (ICU) patients. The HA was measured by a particle-enhanced turbidimetric immunoassay (PETIA) and enzyme-linked immunosorbent assay (ELISA) in a 40-sample dilution series and the 39 ICU patients.
The HA was measured with the PETIA (Corgenix; Broomfield, CO, USA) in ICU samples on the Hitachi 917 (Roche Diagnostics, GmbH; Mannheim, Germany) and in the dilution series on Modular P (Roche Diagnostics GmbH) analyzers (test assay), and by Corgenix HA ELISA using double determination (reference method).
The scientists found that in the ICU patients, the median HA concentration was 159.0 ng/mL (interquartile range (IQR) 117.5–362.5 ng/mL) with ELISA and 157.5 ng/ml (IQR 92.5–359.6 ng/mL) with PETIA. The mean difference was 12.88 ng/mL which was statistically significant and the 95% limits of agreement were −91.17 to 116.9 ng/mL. In the dilution series, the mean difference was −59.26 ng/mL (95% CI, −74.68 to 43.84 ng/mL, and the 95% limits of agreement were 35.23 to −153.8 ng/mL.
The authors concluded that there was random variation between the PETIA and ELISA test that could affect performance in a clinical context. The new clinical biochemistry assay for HA determination will allow for large studies of the clinical utility of HA. The study was published online on December 14, 2015, in the Journal of Clinical Laboratory Analysis.
Related Links:
Nordsjaellands Hospital
Corgenix
Roche Diagnostics GmbH
HA is essentially non-immunogenic, which has excluded direct immunochemical methods of measurement. To accommodate this, several advanced methods of measurements have been used including enzymatic degradation; hyaluronic-binding protein (HABP) linked enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography.
Scientists at the Nordsjaellands Hospital, University of Copenhagen, (Denmark) and their colleagues measured HA concentrations in 39 samples of serum from 39 randomly selected intensive care unit (ICU) patients. The HA was measured by a particle-enhanced turbidimetric immunoassay (PETIA) and enzyme-linked immunosorbent assay (ELISA) in a 40-sample dilution series and the 39 ICU patients.
The HA was measured with the PETIA (Corgenix; Broomfield, CO, USA) in ICU samples on the Hitachi 917 (Roche Diagnostics, GmbH; Mannheim, Germany) and in the dilution series on Modular P (Roche Diagnostics GmbH) analyzers (test assay), and by Corgenix HA ELISA using double determination (reference method).
The scientists found that in the ICU patients, the median HA concentration was 159.0 ng/mL (interquartile range (IQR) 117.5–362.5 ng/mL) with ELISA and 157.5 ng/ml (IQR 92.5–359.6 ng/mL) with PETIA. The mean difference was 12.88 ng/mL which was statistically significant and the 95% limits of agreement were −91.17 to 116.9 ng/mL. In the dilution series, the mean difference was −59.26 ng/mL (95% CI, −74.68 to 43.84 ng/mL, and the 95% limits of agreement were 35.23 to −153.8 ng/mL.
The authors concluded that there was random variation between the PETIA and ELISA test that could affect performance in a clinical context. The new clinical biochemistry assay for HA determination will allow for large studies of the clinical utility of HA. The study was published online on December 14, 2015, in the Journal of Clinical Laboratory Analysis.
Related Links:
Nordsjaellands Hospital
Corgenix
Roche Diagnostics GmbH
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Hemoglobin Testing System
VARIANTnbs
Latest Immunology News
- Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
Channels
Molecular Diagnostics
view channel
Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes
Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations,... Read more
Novel Method Combining Nano Informatics and AI Paves Way for Cancer Blood Tests
Current diagnostic methods for cancer often fall short in terms of precision and efficiency. Traditional techniques, such as imaging scans and tissue biopsies, are invasive, costly, and time-consuming.... Read more
New Assay Detects Heart Failure Biomarker in Less than 11 Minutes
According to the Heart Failure Society of America, nearly 6.5 million Americans over the age of 20 suffer from heart failure, which accounts for about 8.5% of all heart disease deaths in the United States.... Read more
New Method for Lung Microbiomes Analysis Predicts Mortality in Children after Bone Marrow Transplant
Bone marrow transplant, also referred to as hematopoietic cell transplantation (HCT), serves as a critical treatment for children with leukemia, bone marrow failure, and various genetic disorders, including... Read moreHematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel
Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients
Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
AI Predicts Tumor-Killing Cells with High Accuracy
Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read moreMicrobiology
view channel
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces... Read morePathology
view channel
AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time
Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
New Tool Enables Better Classification of Inherited Disease-Causing Variants
Whole genome and exome sequencing are increasingly available for clinical research, aiding in the detection of inherited genetic variants that may cause various diseases. The American College of Medical... Read more
Groundbreaking CRISPR Screen Technology Rapidly Determines Disease Mechanism from Tissues
Thanks to over a decade of advancements in human genetics, scientists have compiled extensive lists of genetic variations linked to a wide array of human diseases. However, understanding how a gene contributes... Read more
Technology
view channel
Microneedle Patch Detects Skin Cancer Early
Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes.... Read more
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
Industry
view channel
Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing
Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")